Calprotectin as a Potential Biomarker for Inflammation in Lung Cancer Patients
Diagnostics · 05.03.2026 · 16 (5) · 780
DOI: 10.3390/diagnostics16050780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 05.03.2026. Verfasst von Selen Karaoğlanoğlu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Faculty of Medicine, Ordu University, 52200 Ordu, Türkiye. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Calprotectin (CLP), a calcium-binding protein complex released predominantly from neutrophils and monocytes, plays a key role in the inflammatory response. Increased levels of CLP have been reported in various inflammatory and malignant conditions. This study aimed to evaluate serum CLP concentrations and their associations with hematological and biochemical parameters in patients with lung cancer.
Methods
This prospective observational study included newly diagnosed lung cancer patients and a healthy control group. Demographic data, routine laboratory parameters, CLP levels, and inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune–inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune–inflammation value (PIV) were recorded. Comparisons were made between groups and across tumor molecular profile, cancer stages, and metastasis status. Correlation and ROC analyses were performed.
Results
Serum CLP levels were significantly higher in the lung cancer group compared with healthy controls (p < 0.001). Among molecular subgroups, patients with positive molecular testing had significantly elevated CLP levels compared with negative and untested groups (p = 0.025). CLP did not differ significantly across cancer stages or metastasis status (p > 0.05). CLP showed a positive correlation with the SIRI (r = 0.323; p = 0.004) and PIV (r = 0.395; p < 0.001). ROC analysis revealed that CLP demonstrated good diagnostic performance for lung cancer, with an AUC of 0.930 (95% CI: 0.849–0.976), sensitivity of 79.5%, and specificity of 92.3%. Among inflammatory indices, PIV (AUC = 0.863) and SIRI (AUC = 0.810) also showed high diagnostic accuracy.
Conclusions
CLP levels are significantly elevated in lung cancer and show strong discriminative ability, outperforming commonly used inflammatory indices. Although CLP is not specific to lung cancer, it may serve as a supportive, noninvasive biomarker reflecting inflammatory burden when interpreted alongside clinical evaluation, imaging findings, and other laboratory parameters.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonology, Faculty of Medicine, Ordu University, 52200 Ordu, Türkiye.
- Department of Medical Genetics, Faculty of Medicine, Aksaray University, 68100 Aksaray, Türkiye.
- Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Ordu University, 52200 Ordu, Türkiye.
ORCID-Profile: Hüseyin Erdal
Zitieren
APA
Karaoğlanoğlu, S., Erdal, H., & Sönmez, M. (2026). Calprotectin as a Potential Biomarker for Inflammation in Lung Cancer Patients. Diagnostics, 16(5), 780. https://doi.org/10.3390/diagnostics16050780
Vancouver
Karaoğlanoğlu S, Erdal H, Sönmez M. Calprotectin as a Potential Biomarker for Inflammation in Lung Cancer Patients. Diagnostics. 2026;16(5):780. doi:10.3390/diagnostics16050780
BibTeX
@article{Karaolanolu2026,
author = {Karaoğlanoğlu, Selen and Erdal, Hüseyin and Sönmez, Müge},
title = {Calprotectin as a Potential Biomarker for Inflammation in Lung Cancer Patients},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {5},
pages = {780},
doi = {10.3390/diagnostics16050780}
}
EUVIMED